Acute Myeloid Leukemia Clinical Trial
Official title:
A Double-blind, Placebo-controlled, Randomized, Multi-center Phase II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
The primary purpose of the study is to determine, whether the addition of Sorafenib to standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results (event free survival).
Status | Completed |
Enrollment | 200 |
Est. completion date | July 2009 |
Est. primary completion date | July 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 61 Years and older |
Eligibility |
Inclusion Criteria: - Patients with newly diagnosed AML (except APL) according to the FAB and WHO classification, including AML evolving from MDS or other hematologic diseases and AML after previous cytotoxic therapy or radiation (secondary AML) - Bone marrow aspirate or biopsy must contain >= 20% blasts of all nucleated cells, with the exception of AML FAB M6, where >= 30% of non-erythroid cells must be leukemic blasts - Age >= 61 years - Informed consent, personally signed and dated to participate in the study - Male patients enrolled in this trial must use adequate barrier birth control measures during the course of the Sorafenib treatment and for at least 3 months after the last administration of Sorafenib Exclusion Criteria: - Central nervous system manifestation of AML - Cardiac Disease: Heart failure NYHA III° or IV°; active coronary artery disease (MI more than 6 months prior to study entry is permitted); serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) - Chronically impaired renal function (creatinin clearance < 30 ml/min) - Chronic pulmonary disease with relevant hypoxia - Inadequate liver function (ALT and AST >= 2.5 x ULN) - Total bilirubin >= 1.5 x ULN - Resting blood pressure (BP) consistently higher than systolic 160 mmHg and/or diastolic 95 mmHg - Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardise compliance with the protocol - Uncontrolled active infection - Concurrent malignancies other than AML - Previous treatment of AML except hydroxyurea and up to 2 days <= 100 mg/m²/d cytarabine - Known HIV and/or hepatitis C infection - Evidence or history of CNS disease, including primary or metastatic brain tumors, seizure disorders - Thrombotic or embolic events such as cerebrovascular accident or pulmonary embolism within 1 year of study entry - Evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy - History of organ allograft - Concomitant treatment with kinase inhibitors, angiogenesis inhibitors and Myelotarg - Patients with major surgery, open biopsy or significant traumatic injury within 4 weeks of start or first dose - Serious, non-healing wound, ulcer or bone fracture - Allergy to study medication or excipients in study medication - Investigational drug therapy outside of this trial during or within 4 weeks of study entry - Patients who are not eligible for standard chemotherapy |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Charité Campus Benjamin Franklin, Med. Klinik III | Berlin | |
Germany | Klinikum Chemnitz GmbH, Klinik für Innere Medizin III | Chemnitz | |
Germany | Universitätsklinikum Carl Gustav Carus der TU Dresden, Medizinische Klinik I | Dresden | |
Germany | St. Johannes Hospital, Medizinische Klinik II | Duisburg | |
Germany | Universitätsklinikum Essen, Zentrum für Innere Medizin, Medizinische Klinik und Poliklinik für Hämatologie | Essen | |
Germany | Klinikum der J. W. Goethe-Universität Frankfurt am Main, Medizinische Klinik II | Frankfurt / Main | |
Germany | Allgemeines Krankenhaus St. Georg, Hämatologische Abteilung | Hamburg | |
Germany | Universitätsklinikum Heidelberg, Med. Klinik V | Heidelberg | |
Germany | Klinikum der Universität zu Köln, Klinik I für Innere Medizin | Köln | |
Germany | Klinikum der Johannes Gutenberg Universität, 3. Medizinische Klinik und Poliklinik | Mainz | |
Germany | Philipps Universität, Abteilung für Hämatologie, Onkologie und Immunologie | Marburg | |
Germany | Klinik für Hämatologie und Onkologie Klinikum Minden | Minden | |
Germany | TU München, Medizinische Klinik III | München | |
Germany | Universitätsklinikum Münster, Medizinische Klinik A | Münster | |
Germany | Klinikum Nürnberg, 5. Medizinische Klinik Einheit für Knochenmarktransplantation | Nürnberg | |
Germany | Universität Regensburg, Abteilung für Hämatologie und Internistische Onkologie | Regensburg | |
Germany | Robert-Bosch Krankenhaus Stuttgart | Stuttgart | |
Germany | Julius-Maximilians-Universität Würzburg, Medizinische Klinik und Poliklinik II | Würzburg |
Lead Sponsor | Collaborator |
---|---|
University Hospital Muenster | Bayer |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Median Event Free Survival of all AML patients | |||
Secondary | Median Event Free Survival of AML patients with Flt3-ITD mutations | |||
Secondary | Median Event Free Survival of the patients in each of the four strata (Flt3 Non-ITD/NPM1 WT, Flt3 Non-ITD/NPM1 mut, Flt3 ITD/NPM1 WT, Flt3 ITD/NPM1 mut) | |||
Secondary | Median Overall Survival of AML patients with Flt3-ITD mutations | |||
Secondary | Median Overall Survival of all AML patients | |||
Secondary | Rate of Complete Remission in all AML patients | |||
Secondary | Rate of Molecular Remission in all AML patients | |||
Secondary | Toxicity | |||
Secondary | Evidence of Minimal Residual Disease in all AML patients | |||
Secondary | Development of Biomarkers indicating the course of disease |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |